Endo International plc - Company Profile (NASDAQ:ENDP)

About Endo International plc - (NASDAQ:ENDP)

Endo International plc - logoEndo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company's subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ENDP
  • CUSIP: 29264F20
  • Web: www.endo.com
Capitalization:
  • Market Cap: $2.64 billion
  • Outstanding Shares: 223,112,000
Average Prices:
  • 50 Day Moving Avg: $11.54
  • 200 Day Moving Avg: $13.27
  • 52 Week Range: $9.70 - $24.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.34
  • P/E Growth: -0.53
Sales & Book Value:
  • Annual Revenue: $4.08 billion
  • Price / Sales: 0.65
  • Book Value: $9.81 per share
  • Price / Book: 1.21
Profitability:
  • EBIDTA: $411.84 million
  • Net Margins: -3.32%
  • Return on Equity: 15.95%
  • Return on Assets: 5.24%
Debt:
  • Debt-to-Equity Ratio: 1.35%
  • Current Ratio: 0.84%
  • Quick Ratio: 0.61%
Misc:
  • Average Volume: 9.20 million shs.
  • Beta: 0.54
  • Short Ratio: 1.6
 

Frequently Asked Questions for Endo International plc - (NASDAQ:ENDP)

What is Endo International plc -'s stock symbol?

Endo International plc - trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International plc -'s earnings last quarter?

Endo International plc - (NASDAQ:ENDP) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.13. The business earned $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. Endo International plc - had a positive return on equity of 15.95% and a negative net margin of 3.32%. The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 EPS. View Endo International plc -'s Earnings History.

What guidance has Endo International plc - issued on next quarter's earnings?

Endo International plc - updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $3.45-3.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.61. The company issued revenue guidance of $3.45-3.60 billion, compared to the consensus revenue estimate of $3.54 billion.

Where is Endo International plc -'s stock going? Where will Endo International plc -'s stock price be in 2017?

18 analysts have issued 12-month target prices for Endo International plc -'s stock. Their predictions range from $12.00 to $35.00. On average, they expect Endo International plc -'s share price to reach $20.00 in the next twelve months. View Analyst Ratings for Endo International plc -.

What are analysts saying about Endo International plc - stock?

Here are some recent quotes from research analysts about Endo International plc - stock:

  • 1. According to Zacks Investment Research, "Endo’s outlook for 2017 was disappointing and lagged expectations. 2017 will continue to challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. In fact, the company’s shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Meanwhile, the company’s Generic segment is under pressure given the challenging competitive landscape and pricing pressures. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. However, Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables." (5/2/2017)
  • 2. JMP Securities analysts commented, "The FDA panel voted 8 yes, 18 no, and 1 abstain on whether Opana ER's benefits outweigh the risk. The FDA was concerned that the new Opana ER formulation just shifts the abuse route from nasal to injections. We do not view Opana ER as a growth driver and it is only 4% of our 2017 revenue estimate while declining 13% y/y. Our $20 price target includes an equal blend of PEG ratio and EV/EBITDA analysis of 1.3x and 8.5x, respectively, on our 2017 estimates." (3/15/2017)
  • 3. Royal Bank of Canada analysts commented, "Yesterday's AdComs' vote of 18 to 8 (one abstain) on OPANA ER's benefits no longer outweighing its risks will push a decision on the product's fate back to FDA. Whether it is removed or sees added restrictions we think it is likely we will see some downward P&L pressure but it is also worth noting that the stock was -25% in Mar ahead of the anticipated panel." (3/15/2017)
  • 4. Mizuho analysts commented, " We still like ENDP and its significant optionality, and we see upside to the stock for the following reasons: (1) Endo can likely sell Xiaflex for a healthy multiple with minimal EBITDA downside after cutting $30M in R&D expense for the planned cellulite trial and expenses tied to ~100 reps. (2) Endo may beat expectations following its conservative guide and/or longer than expected persistence of the Somar business, which is now also for sale. (3) Its high gross margin (55%) generic business with an attractive 117 ANDA pipeline, with 35 "first to files", is likely to attract consolidators in our view. (4) Its U.S.-based manufacturing plants contributed 95% of its production based on revenue, which may appeal to a potential buyer in the current political environment. We attribute remaining risk to a potential increase to the mesh liability accrual, but the company always has the option to litigate and delay. ENDP could therefore work in 2017 following an asset sale or takeover speculation. We reiterate our Buy rating and raise PT to $17 from $15 as we lower our WACC to 10% from 11% after mgmt. re-set expectations and the outlook." (3/3/2017)
  • 5. Guggenheim analysts commented, "ENDP reported a 4Q16 beat and guided down for '17, which was expected given pricing pressure in generics. Lack of earnings visibility in '18 remains a concern. That said, we think patience will be rewarded and execution against its stated objectives will drive multiple expansion for ENDP's stock toward our $35 PT. Also, ENDP continues to be open to strategic alternatives if it cannot enhance shareholder value on its own. We think ENDP could simplify its business by selling its brand assets to pay down debt. In our view, ENDP is also an interesting generics asset (#4 player) in a consolidating industry." (2/28/2017)

Are investors shorting Endo International plc -?

Endo International plc - saw a increase in short interest in April. As of April 28th, there was short interest totalling 22,558,081 shares, an increase of 13.1% from the April 13th total of 19,950,849 shares. Based on an average trading volume of 5,611,281 shares, the short-interest ratio is currently 4.0 days. Approximately 11.3% of the shares of the stock are short sold.

Who are some of Endo International plc -'s key competitors?

Who owns Endo International plc - stock?

Endo International plc -'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.28%), OppenheimerFunds Inc. (1.29%), Bank of New York Mellon Corp (1.02%), First Quadrant L P CA (0.99%), Geode Capital Management LLC (0.87%) and Acadian Asset Management LLC (0.71%). Company insiders that own Endo International plc - stock include Arthur J Higgins, Matthew Joseph Maletta, Michael Hyatt, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Institutional Ownership Trends for Endo International plc -.

Who sold Endo International plc - stock? Who is selling Endo International plc - stock?

Endo International plc -'s stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, State Street Corp, Acadian Asset Management LLC, UBS Asset Management Americas Inc., TIAA CREF Investment Management LLC, Parametric Portfolio Associates LLC, Geode Capital Management LLC and Capstone Asset Management Co.. Company insiders that have sold Endo International plc - stock in the last year include Nancy J Hutson and Roger H Kimmel. View Insider Buying and Selling for Endo International plc -.

Who bought Endo International plc - stock? Who is buying Endo International plc - stock?

Endo International plc -'s stock was purchased by a variety of institutional investors in the last quarter, including First Quadrant L P CA, OppenheimerFunds Inc., Bank of New York Mellon Corp, Ameriprise Financial Inc., American International Group Inc., Nationwide Fund Advisors, Canada Pension Plan Investment Board and Hartford Investment Management Co.. Company insiders that have bought Endo International plc - stock in the last two years include Arthur J Higgins, Matthew Joseph Maletta, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Insider Buying and Selling for Endo International plc -.

How do I buy Endo International plc - stock?

Shares of Endo International plc - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Endo International plc - stock cost?

One share of Endo International plc - stock can currently be purchased for approximately $11.84.

Analyst Ratings

Consensus Ratings for Endo International plc - (NASDAQ:ENDP) (?)
Ratings Breakdown: 12 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $20.00 (68.92% upside)

Analysts' Ratings History for Endo International plc - (NASDAQ:ENDP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017BMO Capital MarketsReiterated RatingHold$16.00HighView Rating Details
5/11/2017Canaccord GenuitySet Price TargetHold$14.00MediumView Rating Details
4/13/2017MizuhoReiterated RatingBuy$17.00 -> $18.00LowView Rating Details
4/8/2017Royal Bank of CanadaSet Price TargetHold$15.00MediumView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
3/15/2017JMP SecuritiesReiterated RatingOutperform$20.00HighView Rating Details
3/11/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
3/1/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
2/28/2017GuggenheimReiterated RatingBuy$35.00N/AView Rating Details
2/6/2017Barclays PLCLower Price TargetEqual Weight$22.00 -> $15.00N/AView Rating Details
1/31/2017Susquehanna Bancshares IncUpgradeNeutral -> PositiveN/AView Rating Details
1/27/2017Piper Jaffray CompaniesSet Price TargetHold$12.00N/AView Rating Details
1/20/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$20.00N/AView Rating Details
1/5/2017Citigroup IncDowngradeBuy -> Neutral$25.00 -> $20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$27.00N/AView Rating Details
9/8/2016Morgan StanleySet Price TargetHold$15.00 -> $16.00N/AView Rating Details
6/29/2016Deutsche Bank AGReiterated RatingBuy$30.00N/AView Rating Details
6/6/2016Goldman Sachs Group IncInitiated CoverageNeutral$20.00N/AView Rating Details
5/18/2016Stifel NicolausLower Price TargetBuy$75.00 -> $25.00N/AView Rating Details
4/2/2016NomuraReiterated RatingBuyN/AView Rating Details
11/13/2015Standpoint ResearchUpgradeHold -> Buy$75.00N/AView Rating Details
6/3/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Endo International plc - (NASDAQ:ENDP)
Earnings by Quarter for Endo International plc - (NASDAQ:ENDP)
Earnings History by Quarter for Endo International plc - (NASDAQ:ENDP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 17$1.10$1.23$1.02 billion$1.04 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.24 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endo International plc - (NASDAQ:ENDP)
2017 EPS Consensus Estimate: $3.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.08$1.26$1.15
Q2 20173$0.71$0.80$0.76
Q3 20173$0.73$0.76$0.74
Q4 20173$0.74$0.86$0.81
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endo International plc - (NASDAQ:ENDP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endo International plc - (NASDAQ:ENDP)
Insider Ownership Percentage: 0.70%
Institutional Ownership Percentage: 95.50%
Insider Trades by Quarter for Endo International plc - (NASDAQ:ENDP)
Institutional Ownership by Quarter for Endo International plc - (NASDAQ:ENDP)
Insider Trades by Quarter for Endo International plc - (NASDAQ:ENDP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.00View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.00View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.00View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.00View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.50View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.00View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.47View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.00View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.00View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.12View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.50View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.00View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.14View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.64View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.00View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.39View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.80View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.00View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Endo International plc - (NASDAQ:ENDP)
Latest Headlines for Endo International plc - (NASDAQ:ENDP)
Source:
DateHeadline
seekingalpha.com logoEndo International plc (ENDP) Presents At UBS Healthcare Conference - Slideshow
seekingalpha.com - May 23 at 12:14 PM
americanbankingnews.com logoEndo International plc - (ENDP) Raised to "Sell" at Vetr Inc.
www.americanbankingnews.com - May 18 at 12:20 AM
americanbankingnews.com logoEndo International plc - (ENDP) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - May 17 at 9:44 PM
americanbankingnews.com logoEndo International plc - (ENDP) PT Set at $14.00 by Canaccord Genuity
www.americanbankingnews.com - May 13 at 6:26 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Endo International plc - (ENDP) Decreased by Analyst
www.americanbankingnews.com - May 12 at 10:20 AM
americanbankingnews.com logoFY2020 EPS Estimates for Endo International plc - (ENDP) Raised by Gabelli
www.americanbankingnews.com - May 11 at 3:40 PM
americanbankingnews.com logoEndo International plc - (ENDP) Short Interest Up 13.1% in April
www.americanbankingnews.com - May 11 at 10:21 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Endo International plc - (ENDP) Decreased by Analyst
www.americanbankingnews.com - May 11 at 10:05 AM
americanbankingnews.com logoEndo International plc - (ENDP) to Post Q2 2017 Earnings of $0.80 Per Share, William Blair Forecasts
www.americanbankingnews.com - May 11 at 8:50 AM
finance.yahoo.com logoEdited Transcript of ENDP earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 7:31 AM
nasdaq.com logoEndo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
www.nasdaq.com - May 9 at 4:55 PM
seekingalpha.com logoEndo International Plc (ENDP) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:55 PM
finance.yahoo.com logoEndo (ENDP) Q1 Earnings Beat Estimates, Revenues in Line
finance.yahoo.com - May 9 at 4:55 PM
finance.yahoo.com logoHere's What's Behind Endo International plc's Rally Today
finance.yahoo.com - May 9 at 4:55 PM
finance.yahoo.com logoEndo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
finance.yahoo.com - May 9 at 4:55 PM
americanbankingnews.com logoEndo International plc - (ENDP) Issues Earnings Results
www.americanbankingnews.com - May 9 at 4:46 PM
americanbankingnews.com logoEndo International plc - (ENDP) Releases FY17 Earnings Guidance
www.americanbankingnews.com - May 9 at 9:15 AM
nasdaq.com logoEndo International plc Earnings Advance 14% In Q1
www.nasdaq.com - May 9 at 7:52 AM
finance.yahoo.com logoEndo Reports First-Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 7:52 AM
finance.yahoo.com logoEndo posts 7.7 percent rise in quarterly revenue
finance.yahoo.com - May 9 at 7:52 AM
finance.yahoo.com logoEndo profit beats on strong sales of generic drugs
finance.yahoo.com - May 9 at 7:52 AM
finance.yahoo.com logoInvestor Network: Endo International Plc to Host Earnings Call
finance.yahoo.com - May 9 at 7:52 AM
marketbeat.com logoEndo reports 1Q loss
marketbeat.com - May 9 at 7:30 AM
nasdaq.com logoCommit To Buy Endo International At $7.50, Earn 18% Using Options - Nasdaq
www.nasdaq.com - May 8 at 4:48 PM
finance.yahoo.com logo[$$] Suits Dog Guggenheim Chief
finance.yahoo.com - May 6 at 10:44 AM
americanbankingnews.com logo Analysts Anticipate Endo International plc - (ENDP) Will Announce Quarterly Sales of $1.03 Billion
www.americanbankingnews.com - May 6 at 10:34 AM
finance.yahoo.com logoIs Endo (ENDP) Poised for a Beat This Earnings Season?
finance.yahoo.com - May 4 at 10:08 PM
americanbankingnews.com logoEndo International plc - (ENDP) Receiving Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 7:58 PM
americanbankingnews.com logo$1.13 EPS Expected for Endo International plc - (ENDP) This Quarter
www.americanbankingnews.com - May 4 at 10:02 AM
americanbankingnews.com logoEndo International plc - (ENDP) Upgraded at Vetr Inc.
www.americanbankingnews.com - May 4 at 1:17 AM
americanbankingnews.com logoVetr Inc. Upgrades Endo International plc - (ENDP) to "Buy"
www.americanbankingnews.com - May 4 at 1:17 AM
finance.yahoo.com logoGenerics Drop Across Board as DOJ Inquiry Expands
finance.yahoo.com - May 3 at 4:50 PM
finance.yahoo.com logoEndo International Plc – Value Analysis (NASDAQ:ENDP) : May 2, 2017
finance.yahoo.com - May 2 at 7:45 PM
americanbankingnews.com logoEndo International plc - (ENDP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 2 at 2:08 PM
americanbankingnews.com logoEndo International plc - (ENDP) Given a $14.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - May 1 at 9:50 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Likely to Affect Endo International plc - (ENDP) Stock Price
www.americanbankingnews.com - May 1 at 6:32 PM
finance.yahoo.com logoEndo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : May 1, 2017
finance.yahoo.com - May 1 at 4:47 PM
americanbankingnews.com logoEndo International plc - (ENDP) Downgraded to "Hold" at Vetr Inc.
www.americanbankingnews.com - April 28 at 8:04 PM
americanbankingnews.com logoEndo International plc - (ENDP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 28 at 6:43 PM
americanbankingnews.com logoVetr Inc. Lowers Endo International plc - (ENDP) to Hold
www.americanbankingnews.com - April 28 at 1:05 AM
americanbankingnews.com logoPositive News Coverage Somewhat Likely to Affect Endo International plc - (ENDP) Share Price
www.americanbankingnews.com - April 27 at 11:00 PM
americanbankingnews.com logoEndo International plc - (ENDP) Short Interest Down 16.9% in April
www.americanbankingnews.com - April 27 at 7:17 AM
finance.yahoo.com logoEndo to Announce First-Quarter 2017 Financial Results
finance.yahoo.com - April 25 at 11:36 AM
americanbankingnews.com logoEndo International plc - (ENDP) Getting Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 4:30 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Endo International plc - (ENDP) Increased by Analyst
www.americanbankingnews.com - April 24 at 8:09 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Impact Endo International plc - (ENDP) Stock Price
www.americanbankingnews.com - April 21 at 7:38 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for Endo International plc -'s Q1 2017 Earnings (ENDP)
www.americanbankingnews.com - April 21 at 8:09 AM
finance.yahoo.com logoBiotech Movers: Organovo, Endo, Omeros
finance.yahoo.com - April 20 at 10:23 AM
americanbankingnews.com logoEndo International plc - (ENDP) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - April 17 at 2:21 PM
americanbankingnews.com logoFavorable Press Coverage Somewhat Likely to Impact Endo International plc - (ENDP) Stock Price
www.americanbankingnews.com - April 15 at 4:03 PM

Social

Endo International plc - (ENDP) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff